Jan 29 (Reuters) - Scholar Rock Holding Corp SRRK.O:
SCHOLAR ROCK SUBMITS BIOLOGICS LICENSE APPLICATION (BLA) TO THE U.S. FDA FOR APITEGROMAB AS A TREATMENT FOR PATIENTS WITH SPINAL MUSCULAR ATROPHY (SMA)
SCHOLAR ROCK HOLDING CORP - TO SUBMIT MAA TO EMA IN 1Q 2025
SCHOLAR ROCK HOLDING CORP - REQUESTS PRIORITY REVIEW FOR APITEGROMAB
Source text: ID:nBw80d9q0a
Further company coverage: SRRK.O